Somatropin - CJ HealthCare Corporation

Drug Profile

Somatropin - CJ HealthCare Corporation

Alternative Names: ALT-P1; CJ-40002; hGH-NexP; Recombinant human growth hormone - CJ Healthcare

Latest Information Update: 18 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CJ Corporation
  • Class Growth hormones; Hormonal replacements
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Somatotropin deficiency

Most Recent Events

  • 26 Apr 2017 Alteogen and Cristalia sign a letter of intent to co-promote and co-develop somatropin in Latin America for Somatropin deficiency
  • 26 Apr 2017 Alteogen files an IND application with the Korea Food and Drug Administration in Korea for Somatropin deficiency
  • 29 Jul 2016 Final safety and pharmacokinetics data from a phase I trial in healthy volunteers presented at The 98th Annual Meeting of the Endocrine Society (ENDO-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top